Skip to main content

Tasly In-licenses Two Cell Therapy Treatments in $90 Million Deal

China 's Tasly Pharma has in-licensed China rights to two heart drugs from Mesoblast of Australia in a $90 million agreement. Tasly will develop, manufacture and sell two Mesoblast allogeneic mesenchymal precursor cell (MPC) candidates: MPC-150-IM to treat or prevent chronic heart failure and MPC-25-IC to treat or prevent acute myocardial infarction. Tasly will pay $40 million upfront -- a $20 million payment and a $20 million investment in Mesoblast. More details.... Stock Symbols: (SHA: 600535) (NSDQ: MESO; ASX: MSB) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.